Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Randomized, Open Label, Active-Controlled, Dose Escalation, Multi-center Study to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Tetanus/Diphtheria/Pertussis Booster Vaccine (Tdap-1018) Compared to a Licensed Tdap Vaccine in Healthy Volunteers Between 10 and 22 Years of Age

Next Previous
X
Search
Trial Profile

A Phase 1 Randomized, Open Label, Active-Controlled, Dose Escalation, Multi-center Study to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Tetanus/Diphtheria/Pertussis Booster Vaccine (Tdap-1018) Compared to a Licensed Tdap Vaccine in Healthy Volunteers Between 10 and 22 Years of Age

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adjuvanted pertussis vaccine-Dynavax Technologie's/Serum Institute of India (Primary)
  • Indications Diphtheria; Pertussis; Tetanus
  • Focus Adverse reactions
  • Sponsors Dynavax Technologies

    • Most Recent Events

    • 03 Nov 2022 According to a Dynavax Technologies media release, data from this study were presented at the ID Week 2022.
    • 04 Aug 2022 According to a Dynavax Technologies media release, the company previously reported interim adult data from an on-going Phase 1 clinical trial evaluating the Company's adjuvanted Tdap vaccine candidate demonstrated it was well tolerated without safety concerns with immunogenicity data supporting continued advancement.
    • 04 Aug 2022 According to a Dynavax Technologies media release, adolescent data from this trial is anticipated in the fourth quarter of 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top